DiaTech Oncology will invest $2.7 million to expand its operations center in Franklin, Tennessee
, with the opening of a laboratory expected to create 39 specialized positions during the next two years in Williamson County.
“DiaTech is pleased to begin its first U.S. laboratory operation in Franklin, Tennessee,” DiaTech Oncology President Garry Latimer said. “This laboratory is under development with a planned opening of its specialized ‘Correct Chemo Assay’ cancer testing facility in early 2014.”
“DiaTech’s test is the only test on the market that reveals to the treating oncologist the most effective chemotherapy for inducing cell death in the malignant cells of a particular cancer patient. As our clinical studies show, DiaTech’s test can guide therapy in individual patients,” DiaTech Oncology Chief Medical Officer Cary Presant, M.D., said.
The 39 new jobs include technical staffing positions for medical technologists with extensive experience in isolation, purification and culturing of tumor cells from human tissues, diagnostic multiparameter flow cytometry, and histology and immunohistochemistry.
“Tennessee is a top state when it comes to research and development expenditures, and we are focused on leveraging our remarkable R&D assets, along with our strengths in the health care industry, to attract innovative companies like DiaTech to locate and expand in our state,” Economic and Community Development Commissioner Bill Hagerty said. “I appreciate DiaTech for their investment in Williamson County that will not only benefit our citizens and economy, but cancer patients and physicians worldwide.”
“Health care is one of the foundational economic sectors in Williamson County,” Williamson County Chamber of Commerce President and CEO Matt Largen said. “DiaTech’s laboratory operation will help us diversify the healthcare sector by capturing the increasingly important research and development component. I am thankful DiaTech selected Williamson County and look forward to partnering with them to grow their presence here.”